Expired activity Please go to the PowerPak
homepage and select a course.
Considerations for Individualizing CDK 4/6 Inhibitor Therapy in Breast Cancer: Examining the Data and Agent-Specific Attributes (Recorded Podcast)
References »
FACULTY
Rodney J. Hunter, PharmD, BCOP
Clinical Assistant Professor, Pharmacy Practice
Texas Southern University College of Pharmacy and Health Sciences
Clinical Pharmacy Specialist, Breast Oncology
University of Texas Health Memorial Hermann Cancer Center
Houston, TX
Amy L. Indorf, PharmD, BCOP
Clinical Oncology Pharmacist
UW Medicine
Seattle Cancer Alliance
Seattle, WA
Upon completion of this program, participants should be better able to:
Discuss the mechanism of action, indications, and guideline recommendations for CDK 4/6 inhibitors in patients with HR+/HER2– advanced or metastatic breast cancer
Evaluate agent-specific efficacy and toxicity profiles of CDK 4/6 inhibitors to effectively individualize patient care
Your browser does not support the 'audio' tag
Back to Top